Skip to main content

Advertisement

SpringerLink
Log in

A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms

  • Nonstatin Drugs (L. Tokgozoglu and A.L. Catapano, Section Editors)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To provide a systematic approach to management of the patient with statin-attributed muscle symptoms.

Recent Findings

We examined the prevalence of statin intolerance, the role of the nocebo effect, key findings in the patient’s history and laboratory studies, the potential value of coronary calcium scoring, and the importance of shared decision-making in considering statin re-initiation.

Summary

Most patients with statin-attributed muscle symptoms can be successfully treated with statins or a combination of statins and non-statins to achieve successful ASCVD risk reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cholesterol Treatment Trialists C, Fulcher J, O’Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405.

    Article  Google Scholar 

  2. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90.

    Article  Google Scholar 

  3. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–96.

    Article  CAS  PubMed  Google Scholar 

  4. Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation. 2017;136(20):1878–91.

    Article  CAS  PubMed  Google Scholar 

  5. Cholesterol Treatment Trialists C. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–15.

    Article  Google Scholar 

  6. Boersma E, Kardys I. The legacy of HOPE-3. Eur Heart J. 2021;42(31):3008–10.

    Article  PubMed  Google Scholar 

  7. Penson PE, Bruckert E, Marais D, et al. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J Cachexia Sarcopenia Muscle. 2022;13(3):1596–622. https://doi.org/10.1002/jcsm.12960.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015;9(2):129–69.

    Article  PubMed  Google Scholar 

  9. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Mancini GBJ, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016;32(7, Supplement):S35–65.

    Article  PubMed  Google Scholar 

  11. Sposito AC, FariaNeto JR, Carvalho LS, et al. Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. Curr Med Res Opin. 2017;33(2):239–51.

    Article  CAS  PubMed  Google Scholar 

  12. Rosenson RS, Miller K, Bayliss M, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31(2):179–86.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410.

    Article  CAS  PubMed  Google Scholar 

  14. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.

    Article  CAS  PubMed  Google Scholar 

  15. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.

    Article  CAS  PubMed  Google Scholar 

  16. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15.

    Article  PubMed  Google Scholar 

  17. •• Bytyci I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;ehac015. https://doi.org/10.1093/eurheartj/ehac015. This meta-analysis estimates the prevalence of statin intolerance, employing major stakeholder diagnostic criteria, and identifies risk factors and conditions that are associated with increased the risk of statin-associated muscle symptoms.

  18. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. J Am Med Assoc. 2002;287(5):622–7.

    Article  Google Scholar 

  19. Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–90.

    Article  CAS  PubMed  Google Scholar 

  20. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287(5):622–7.

    Article  PubMed  Google Scholar 

  21. Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Herrett E, Williamson E, Brack K, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135. https://doi.org/10.1136/bmj.n135.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Wood FA, Howard JP, Finegold JA, et al. N-of-1 Trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383(22):2182–4.

    Article  PubMed  Google Scholar 

  24. Kalra DK. Bridging the racial disparity gap in lipid-lowering therapy. J Am Heart Assoc. 2021;10(1): e019533.

    Article  PubMed  Google Scholar 

  25. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med. 2008;359(8):789–99.

    Article  CAS  PubMed  Google Scholar 

  27. Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb. 2017;24(1):19–25.

    Article  PubMed  PubMed Central  Google Scholar 

  28. • Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81. This scientific statement from the American Heart Association provides a comprehensive overview of statin safety and statin associated adverse events in multiple population groups and in individuals with a variety of chronic disease states.

    Article  CAS  PubMed  Google Scholar 

  29. Lee JW, Morris JK, Wald NJ. Grapefruit Juice and Statins. Am J Med. 2016;129(1):26–9.

    Article  CAS  PubMed  Google Scholar 

  30. Serban MC, Colantonio LD, Manthripragada AD, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69(11):1386–95.

    Article  CAS  PubMed  Google Scholar 

  31. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–8.

    Article  CAS  PubMed  Google Scholar 

  32. Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015;66(15):1657–68.

    Article  CAS  PubMed  Google Scholar 

  33. Grundy SM, Stone NJ. 2018 American Heart Association/American College of Cardiology/Multisociety guideline on the management of blood cholesterol-secondary prevention. JAMA Cardiol. 2019;4(6):589–91.

    Article  PubMed  Google Scholar 

  34. Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. The Lancet. 2011;378(9792):684–92.

    Article  CAS  Google Scholar 

  35. Orringer CE, Maki KC. HOPE for rational statin allocation for primary prevention: a coronary artery calcium picture is worth 1000 words. Mayo Clin Proc. 2020;95(8):1740–9.

    Article  CAS  PubMed  Google Scholar 

  36. Orringer CE, Blaha MJ, Stone NJ. Coronary artery calcium scoring in patients with statin associated muscle symptoms: prescribing statins for those most likely to benefit. J Clin Lipidol. 2021;15(6):782–8.

    Article  PubMed  Google Scholar 

  37. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526–34.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Juszczyk MA, Seip RL, Thompson PD. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev Cardiol. 2005;8(4):197–9.

    Article  PubMed  Google Scholar 

  39. Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol. 2008;101(12):1747–8.

    Article  CAS  PubMed  Google Scholar 

  40. Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7): e011662.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203.

    Article  CAS  PubMed  Google Scholar 

  42. Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8(6):554–61.

    Article  PubMed  Google Scholar 

  43. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520–30.

    Article  CAS  PubMed  Google Scholar 

  44. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–19.

    Article  CAS  PubMed  Google Scholar 

  45. Banach M, Patti AM, Giglio RV, et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72(1):96–118.

    Article  PubMed  Google Scholar 

  46. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. The National Lipid Association’s Muscle Safety Expert P. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58-71.

    Article  PubMed  Google Scholar 

  47. McMahon GM, Zeng X, Waikar SS. A risk prediction score for kidney failure or mortality in rhabdomyolysis. JAMA Intern Med. 2013;173(19):1821–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119(5):400–9.

    Article  CAS  PubMed  Google Scholar 

  49. Wiggins BS, Saseen JJ, Page RL, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–95.

    Article  PubMed  Google Scholar 

  50. Blaier O, Lishner M, Elis A. Managing statin-induced muscle toxicity in a lipid clinic. J Clin Pharm Ther. 2011;36(3):336–41.

    Article  CAS  PubMed  Google Scholar 

  51. Needham M, Fabian VA, Knezevic W, Panegyres PK, Zilko PJ, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007;17:194–200.

    Article  PubMed  Google Scholar 

  52. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16(12):689–701.

    Article  CAS  PubMed  Google Scholar 

  54. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410.

    Article  CAS  PubMed  Google Scholar 

  55. Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord. 2018;28(1):87–99.

    Article  PubMed  Google Scholar 

  56. Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015;373(17):1680–2.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Cardiovascular Division, University of Miami Miller School of Medicine, 1120 NW 14th Street, Suite 1111, Miami, FL, 33136, USA

    Carl E. Orringer

  2. Department of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Jelani K. Grant

  3. Department of Cardiology, Hacettepe University, Ankara, Turkey

    Lale Tokgozoglu

Authors
  1. Carl E. Orringer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jelani K. Grant
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lale Tokgozoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carl E. Orringer.

Ethics declarations

Conflict of Interest

Dr. Orringer and Grant have no conflicts or competing interests relevant to this manuscript. Dr. Tokgozoglu reports participation in a Data Safety Monitoring Board or Advisory Board for Abbott, Amgen, Novartis, Sanofi, Daiichi-Sankyo, Mylan, Pfizer. She also reports payment/honoraria from Abbott, Amgen, Daiichi Sankyo, MSD, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, and Recordati, as well as consulting fees from Abbott, Amgen, Bayer, MSD, Novartis, Sanofi, Novo Nordisk, and Daiichi Sankyo, and she reports being the Past President of the European Atherosclerosis Society and the Past President of the Turkish Society of Cardiology.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Nonstatin Drugs

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Orringer, C.E., Grant, J.K. & Tokgozoglu, L. A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms. Curr Atheroscler Rep 24, 839–847 (2022). https://doi.org/10.1007/s11883-022-01059-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-022-01059-x

Keywords

Search

Navigation